CollPlant Biotechnologies Ltd. (CLGN)

CollPlant Biotechnologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2.48	0.52	10.96	0.3	15.64	6.14
Revenue Growth (YoY)	280.77%	-95.30%	3565.22%	-98.09%	154.86%	164.75%
Cost of Revenue	0.92	1.63	1.99	0.4	2.01	3
Gross Profit	1.56	-1.11	8.97	-0.1	13.64	3.14
Selling, General & Admin	5.12	5.63	6	6.74	5.94	4.67
Research & Development	8.75	10.52	10.48	10.26	7.63	4.07
Total Operating Expenses	13.87	16.14	16.48	17	13.57	8.73
Operating Income	2.66	17.25	7.51	17.1	0.07	-5.6
Total Non-Operating Income (Expense)	0.15	0.64	0.49	0.17	0.17	-0.18
Pretax Income	2.8	17.89	8.01	17.27	0.24	-5.77
Net Income	-12.16	-16.61	-7.02	-16.93	0.24	-5.77
Net Income to Common	-12.16	-16.61	-7.02	-16.93	0.24	-5.77
Shares Outstanding (Basic)	679	11	11	9	10	7
Shares Outstanding (Diluted)	679	11	11	9	12	7
Shares Change (YoY)	145.68%	4.56%	22.34%	-25.17%	73.76%	38.12%
EPS (Basic)	-1.88	-1.45	-1.10	-1.90	0.02	-0.84
EPS (Diluted)	-1.88	-1.45	-1.10	-1.90	0.02	-0.84
Free Cash Flow	-7.14	-14.58	-3.72	-14.97	1.07	-4.89
Free Cash Flow Per Share	-0.01	-1.27	-0.34	-1.67	0.09	-0.71
Gross Margin	63.03%	-215.53%	81.83%	-33.78%	87.18%	51.08%
Operating Margin	430.67%	3349.71%	68.55%	5718.06%	0.42%	-91.23%
Profit Margin	436.61%	3474.37%	73.04%	5775.59%	1.52%	-94.09%
FCF Margin	-288.28%	-2830.29%	-33.92%	-5007.36%	6.86%	-79.65%
EBITDA	11.6	18.29	8.61	18.17	0.84	-4.94
EBITDA Margin	468.57%	3551.26%	78.60%	6077.93%	5.36%	-80.48%
EBIT	2.66	17.25	7.51	17.1	0.07	-5.6
EBIT Margin	430.67%	3349.71%	68.55%	5718.06%	0.42%	-91.23%

Updated Nov 26, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q